Waldenstrom Macroglobulinemia clinical trials at UC Health
4 in progress, 2 open to eligible people
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
open to eligible people ages 18 years and up
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
at UCSF
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
open to eligible people ages 18 years and up
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.
at UC Irvine UCSD
A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Sorry, in progress, not accepting new patients
This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 (Zanubrutinib) vs ibrutinib in subjects with MYD88 Mutation Waldenström's Macroglobulinemia.
at UCSD
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety and efficacy of Ibrutinib in combination with Rituximab in subjects with Waldenström's Macroglobulinemia.
at UCLA
Last updated: